[HTML][HTML] A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern
Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that affects
older adults with frequent comorbidities, making real-world treatment decisions challenging …
older adults with frequent comorbidities, making real-world treatment decisions challenging …
[HTML][HTML] Comparison of survival by multimodal treatment regimen among malignant pleural mesothelioma patients in an integrated health system
KC Banks, S Ossowski, YY Hung, DS Hsu… - Clinical Lung Cancer, 2022 - Elsevier
Background Optimal therapy for malignant pleural mesothelioma (MPM) remains unclear.
We compared overall survival in patients with MPM after various multimodal treatment …
We compared overall survival in patients with MPM after various multimodal treatment …
Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes
Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …
Meta-analysis of survival and development of a prognostic nomogram for malignant pleural mesothelioma treated with systemic chemotherapy
Simple Summary Malignant pleural mesothelioma (MPM) is a rare cancer with an
aggressive disease course. For patients who are medically inoperable or surgically …
aggressive disease course. For patients who are medically inoperable or surgically …
Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma
Importance Some recently proposed frontline therapies for malignant pleural mesothelioma
(MPM) are very costly, yet their impact on quality of life and overall survival of these patients …
(MPM) are very costly, yet their impact on quality of life and overall survival of these patients …
[HTML][HTML] A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural …
Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy
characterised by limited treatment options and a poor prognosis. At relapse after platinum …
characterised by limited treatment options and a poor prognosis. At relapse after platinum …
Salvage therapy for relapsed malignant pleural mesothelioma: A systematic review and network meta-analysis
Simple Summary Malignant pleural mesothelioma (MPM) is an aggressive cancer with
limited therapeutic options. Pemetrexed plus platinum is a standard first-line therapy, but …
limited therapeutic options. Pemetrexed plus platinum is a standard first-line therapy, but …
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label …
Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
S Cedres, JD Assaf, P Iranzo, A Callejo, N Pardo… - Scientific Reports, 2021 - nature.com
CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with
some differences in the efficacy of chemotherapy according to histology. The objective of this …
some differences in the efficacy of chemotherapy according to histology. The objective of this …
Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic …
SA Srour, JA Stoner - 2016 - ascopubs.org
8554 Background: Pemtrexed/cisplatin (PCisp) remains the standard frontline treatment for
advanced-stage MPM. However, a majority of patients are older and too fragile to tolerate …
advanced-stage MPM. However, a majority of patients are older and too fragile to tolerate …